TABLE 1.
Male control | Male halo | Male cloz | Female control | Female halo | Female cloz | |
---|---|---|---|---|---|---|
Protein level membrane | ||||||
Hypothalamus (mg/ml) | 9.08 ± 0.23 | 8.67 ± 0.14 | 8.74 ± 0.34 | 9.10 ± 0.31 | 8.86 ± 0.22 | 8.89 ± 0.33 |
Protein level cytosol | ||||||
Hypothalamus (mg/ml) | 9.17 ± 0.40 | 10.00 ± 0.35 | 9.11 ± 0.40 | 8.76 ± 0.33 | 8.49 ± 0.44 | 9.20 ± 0.46 |
Albumin | ||||||
Hypothalamus (mg/ml) | 9.14 ± 0.81 | 8.99 ± 0.59 | 7.3 ± 0.53 | 7.22 ± 0.60 | 7.39 ± 0.51 | 8.00 ± 0.54 |
Oxidative stress | ||||||
Hypothalamus (MDAµmol/ml) | 0.037 ± 0.007 | 0.029 ± 0.006 | 0.025 ± 0.006 | 0.034 ± 0.01 | 0.032 ± 0.01 | 0.034 ± 0.007 |
Fasting glucose | ||||||
Serum (µg/ml) | 47.46 ± 5.44 | 64.05 ± 4.58 | 57.22 ± 3.81 | 34.37 ± 1.59 | 40.33 ± 5.45 | 45.42 ± 2.99* |
Total glucose | ||||||
Hypothalamus (µg/ml) | 8.70 ± 2.1 | 13.59 ± 3.2 | 7.89 ± 1.5 | 7.02 ± 1.2 | 8.85 ± 1.5 | 9.41 ± 1.9 |
Glycogen | ||||||
Hypothalamus (µg/ml) | 4.87 ± 0.52 | 4.38 ± 0.53 | 3.98 ± 0.75 | 5.24 ± 0.59 | 5.16 ± 0.91 | 5.41 ± 0.64 |
Lactate | ||||||
Hypothalamus (mmol/L) | 2.06 ± 0.072 | 2.14 ± 0.076 | 2.25 ± 0.085 | 2.05 ± 0.059 | 2.21 ± 0.072 | 2.31 ± 0.095* |
Pyruvate | ||||||
Hypothalamus (µmol/L) | 64.64 ± 11.5 | 58.14 ± 7.1 | 47.71 ± 10.3 | 50.07 ± 12.02 | 41.93 ± 5.0 | 63.64 ± 13.8 |
Lactate/pyruvate ratio | ||||||
Hypothalamus | 40.95 ± 6.2 | 41.42 ± 4.8 | 70.04 ± 14.7 | 68.67 ± 16.9 | 59.23 ± 6.5 | 58.33 ± 17.3 |
cloz, clozapine medicated; halo, haloperidol medicated; with n group = 10.
p < .05 and **p < .001 as significant.